Page last updated: 2024-09-03

mk 0663 and Laryngitis

mk 0663 has been researched along with Laryngitis in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Almeida, A; Baltazar, F; Castro, AG; Cruz, A; Lamas, N; Lima-Rodrigues, M; Oliveira, P; Pedrosa, J; Reis, RM; Valle-Fernandes, A; Vieira, A	1

Other Studies

1 other study(ies) available for mk 0663 and Laryngitis

Article	Year
The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2010, Volume: 59, Issue:9 Topics: Animals; Calcitonin Gene-Related Peptide; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Etoricoxib; Interleukin-10; Interleukin-1beta; Interleukin-6; Laryngitis; Male; Pyridines; Rats; Rats, Wistar; Substance P; Sulfones; Tumor Necrosis Factor-alpha	2010

Article

Year

The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment.

Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2010, Volume: 59, Issue:9

Topics: Animals; Calcitonin Gene-Related Peptide; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Etoricoxib; Interleukin-10; Interleukin-1beta; Interleukin-6; Laryngitis; Male; Pyridines; Rats; Rats, Wistar; Substance P; Sulfones; Tumor Necrosis Factor-alpha

2010